Deucravacitinib in Psoriatic Disease
In this episode of Inside GRAPPA, Dr. Andre Lucas Ribeiro, Dr. Anna López Ferrer, and Professor Philip J. Mease explore the role of deucravacitinib, a selective TYK2 inhibitor, in the evolving treatment landscape of psoriatic disease.
Together, they examine the unmet needs in psoriasis and psoriatic arthritis, discuss the clinical evidence supporting deucravacitinib's efficacy and safety, and consider its potential place among existing treatment options. The conversation also highlights the importance of individualized treatment decisions, remaining evidence gaps, and future research…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.